While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option. Jessica is a writer on the Wellness team with a focus on health technology ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus ...